Innate cell engager NK cell combination therapy - Affimed Therapeutics
Alternative Names: ICE® + NK cell therapy - Affimed TherapeuticsLatest Information Update: 16 Mar 2022
At a glance
- Originator Affimed Therapeutics
- Developer Affimed Therapeutics; Unknown
- Class Natural killer cell therapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified